Advertisement

Merck

Latest Stories

Molnupiravir is only 30% effective at preventing COVID hospitalization after symptoms appear, but it will be more available. Photo: Tang Yanjun/China News Service via Getty Images

It is now the second at-home COVID treatment option in pill form, following Pfizer’s, which got authorization on Dec. 22.